We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

CSF Glucose Unaltered in Patients With Dementia

By LabMedica International staff writers
Posted on 14 Dec 2022
Print article
Image: The cobas 8000 modular analyzer series is a scalable module based serum work area (SWA) solution for a wide range of in vitro diagnostics testing of clinical chemistry & immunochemistry designed for high throughput laboratories (Photo courtesy of Roche Diagnostics)
Image: The cobas 8000 modular analyzer series is a scalable module based serum work area (SWA) solution for a wide range of in vitro diagnostics testing of clinical chemistry & immunochemistry designed for high throughput laboratories (Photo courtesy of Roche Diagnostics)

A plethora of the pathological processes of many dementia disorders begin several years before the clinical expression of the diseases, and for that reason it is important to discover new biomarkers and methods to detect these processes at an early stage.

Glucose is transported from the blood, through the blood brain barrier (BBB), and into the interstitial space, where it is made available for metabolism by astrocytes and neurons. Normally, there is a close relationship between cerebrospinal fluid (CSF) and plasma glucose concentrations, and the ratio ranges between 0.5 and 0.8, but the ratio may change in different pathological conditions.

Clinical Scientists at the Copenhagen University Hospital Rigshospitalet (Copenhagen, Denmark) and their colleagues collected CSF and plasma samples from patients referred for diagnostic evaluation. The samples were taken from 446 patients (Alzheimer’s Disease (AD) (n=320), vascular dementia (VaD) (n=64), frontotemporal dementia (FTD) (n=27) and dementia with Lewy bodies (DLB) (n=35)), and 130 healthy controls (HC) (healthy subjects (HS) (n=34), non-demented HS (n=96)).

CSF was collected in 5 mL polypropylene tubes, transported at room temperature, and analyzed on a Radiometer ABL instrument (Radiometer Medical ApS, Brønshøj, Denmark) within an hour after sampling. Plasma was collected in 2 mL Greiner bio-one VACUETTE tubes with Sodium Fluoride/Potassium Oxalate (Greiner, Kremsmünster, Austria), transported at room temperature, and analyzed on a COBAS 8000 instrument (Roche Diagnostics, Indianapolis, IN, USA) within three hours after sampling.

The investigators reported that no significant differences in CSF and plasma glucose levels between the dementia group and HC were found. Furthermore, no significant difference in the CSF/plasma glucose ratio was identified. When investigating CSF glucose, plasma glucose and the CSF/plasma glucose ratio for the different etiologies within the dementia group, no significant differences were found. In addition, no statistically significant differences were found in the relationship between age and CSF glucose, plasma glucose and the CSF/plasma glucose ratio.

The authors concluded that despite severe reductions in the glucose metabolism in the brain of patients with dementia disorders, CSF and plasma glucose levels and the CSF/plasma-glucose ratio do not reflect this hypometabolism, and do not differentiate between dementia of different etiologies. For that reason, it is unlikely that they will have diagnostic potential in a mixed memory clinic setting. The study was published on December 8. 2022 in the journal Clinical Biochemistry.

Related Links:
Copenhagen University Hospital Rigshospitalet
Radiometer Medical
Greiner
Roche Diagnostics

HLX
Gold Supplier
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
New
Auto Clinical Chemistry Analyzer
ChemiLab 100
New
Helminth Multiplex PCR Assay
Allplex GI-Helminth(I) Assay

Print article

Channels

Hematology

view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more

Immunology

view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more

Microbiology

view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more

Pathology

view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more

Technology

view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more

Industry

view channel
Image: The global HbA1c testing devices market is expected to reach USD 2.56 billion in 2027 (Photo courtesy of Freepik)

Global Hemoglobin A1c Testing Devices Market Driven by Rising Prevalence of Diabetes

Hemoglobin A1c (HbA1c), or glycated hemoglobin, refers to hemoglobin with glucose attached. HbA1c testing devices are used for blood tests that determine average blood glucose, or blood sugar levels.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.